Drug Cocktail Significantly Reduced Severe COVID, Death in Outpatients
10/01/2021
A monoclonal antibody combination of casirivimab and imdevimab (REGEN-COV) significantly reduced the risk of COVID-19–related hospitalizations and death from any cause in the phase 3 portion of an adaptive trial of outpatients, according to a Medscape report.
Researchers, led by David Weinreich, MD, MBA, executive vice president of the drug cocktail's manufacturer Regeneron, found in the randomized trial that the combination also resolved symptoms and reduced the SARS-CoV-2 viral load more quickly compared with placebo.
Findings were published online Wednesday in the New England Journal of Medicine.